logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics hails 'transformational' deal with US firm Mallinckrodt

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses the partnership they've struck with US biopharmaceutical firm Mallinckrodt PLC (NYSE: MNK) to develop and commercialise gene silencing treatments for serious diseases.

Mallinckrodt will obtain an exclusive worldwide license to Silence's SLN500 asset, which uses RNA interference – therapeutics designed to inhibit or “silence” a group of proteins in the immune system that play a role in the development of inflammation, contributing to many diseases.

Mallinckrodt will provide Silence with an upfront payment of US$20mln

Quick facts: Silence Therapeutics PLC

Price: 437 GBX

AIM:SLN
Market: AIM
Market Cap: £361.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics - Proactive One2One Virtual Event

Rob Quinn, from Silence Therapeutics (LON:SLN) pitches the company to investors at the Proactive One2One Virtual Event. Silence develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can...

1 day, 10 hours ago

2 min read